No rankings that’s always accurate. Generally
1. Precedent Transactions is greater than Comparable Companies due to Control Premium built into acquisitions
2. DCF is the most variable, it can sometimes be the highest and sometimes be the lowest
Because scientists and subscribers are “available” and impact all stakeholders.
Could go either way, but most cases LBO give a lower valuation.
- LBO: don’t get any value from the cash flow between year 1 and the final year; only valuing based on terminal value
- DCF considers both the company’s cash flows in between and its terminal value, so values tend to be higher.
football field graph
The same way you would value a company:
- look at comparable apple trees are worth
- value of the apple tree’s cash flow
Because EBITDA is available to all stakeholders. Enterprise value is also available to all stakeholders.
If the EBITDA multiple median is 8x, and you’re company’s EBITDA is $500 million, the implied value is 4 billion